AHA: Cannabis May Have Adverse Cardiovascular Effects
No indication of cardiovascular benefits found; more research needed to further understand adverse effects.
Cardiovascular Disease
USPSTF Still Advises Against Carotid Artery Stenosis Screening
Harms of screening for asymptomatic carotid artery stenosis outweigh benefits in general population.
Empagliflozin Heart Failure Study Meets Primary End Point
The double-blind EMPEROR-Reduced trial enrolled 3730 adults with HFrEF, with and without diabetes.
FDA to Review Furosemide Formulation Delivered Via On-Body Infusor
Furoscix is an investigational, proprietary, pH-neutral formulation of furosemide designed for subcutaneous administration via a wearable, pre-programmed on-body drug delivery system for outpatient self-administration.
Trial Investigating Dapagliflozin in CKD Meets All End Points
The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
Mavacamten Gets Breakthrough Therapy Status for Obstructive Hypertrophic Cardiomyopathy
The designation is supported by results from the phase 3 EXPLORER-HCM trial that evaluated mavacamten in 251 adult patients with symptomatic, obstructive HCM.
High Prevalence of Americans Have Conditions Linked to Severe COVID-19
Median prevalence of any underlying medical condition 47.2% for residents in all 50 states, DC.
Spironolactone Use Associated With Reduced Prostate Cancer Risk
Men who had ever used spironolactone had decreased odds of prostate cancer compared with never-users, according to a study.
GI Bleeding Rates With P2Y12 Platelet Inhibitors Compared
Ticagrelor and prasugrel, the newer generation of P2Y12-inhibiting antiplatelet agents, were found to be associated with fewer gastrointestinal bleeding events the first year after percutaneous coronary intervention compared with clopidogrel.
Dapagliflozin Fast-Tracked for Heart Failure Following Acute MI
The FDA has granted Fast Track designation to dapagliflozin (Farxiga; AstraZeneca) to reduce the risk of hospitalization for heart failure or cardiovascular (CV) death in adults following an acute myocardial infarction.
